Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 ccRCC samples. (PDF 108 kb
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S5. Summary of results from univariate and multivariable Cox regression for overall survival o...
Figure S1. Flow chart of included patients. Table S2. Table resuming patients âcharacteristics. Ta...
Table S7. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S3. Survival analysis based on Risk Score at diagnosis. Kaplan-Meier cancer specific survival...
Table S6. Clinicopathological parameters for tumors included in the heterogeneity analysis. (PDF 65 ...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Table S8. Top 20 most significant GO Terms for GeneIDs either hyper- or hypomethylated in M0-P and M...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Additional file 1: Figure S1. The relationship between DDR mutation and clinical outcome in the TCGA...
Figure S4. The CLDN7 promoter DNA methylation site, cg00072720, was associated with poor overall sur...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S5. Summary of results from univariate and multivariable Cox regression for overall survival o...
Figure S1. Flow chart of included patients. Table S2. Table resuming patients âcharacteristics. Ta...
Table S7. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S3. Survival analysis based on Risk Score at diagnosis. Kaplan-Meier cancer specific survival...
Table S6. Clinicopathological parameters for tumors included in the heterogeneity analysis. (PDF 65 ...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Table S8. Top 20 most significant GO Terms for GeneIDs either hyper- or hypomethylated in M0-P and M...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Additional file 1: Figure S1. The relationship between DDR mutation and clinical outcome in the TCGA...
Figure S4. The CLDN7 promoter DNA methylation site, cg00072720, was associated with poor overall sur...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S5. Summary of results from univariate and multivariable Cox regression for overall survival o...
Figure S1. Flow chart of included patients. Table S2. Table resuming patients âcharacteristics. Ta...
DOI
Add to ORKG